Read Larry Connors' blog – Short Term Trading Strategies
Using Xybion's Standard Validation Package to accelerate its implementation and validation of Pristima, Calvert was able to leverage its internal resources to execute the validation along with Xybion's installation, training and configuration services. Calvert's project to implement Pristima is part of a larger effort to enhance its technical capabilities to further automate data collection, accelerate study reporting and to add the ability to post results to their clients utilizing near real-time technologies .
Dr. Pradip Banerjee, Xybion's Chief Executive Officer, stated "We are proud to add Calvert Labs to the Xybion client community. This is a world-class contract research organization serving the pharmaceutical and biotechnology industries and we are pleased that they have moved quickly to license, validate and place the system into production." Dr. Banerjee added, "Their strategy to take on a wider variety of studies, offer more flexibility in their study designs and to make study reports available to clients quickly, fits right in with Xybion's strategy to provide the most comprehensive, flexible, and powerful system on the market. We are tremendously satisfied that Calvert has acknowledged Xybion as its ideal information systems partner and is integrating the Pristima preclinical solution into its full array of products and services. "
Allan Reiss, CEO of Calvert Labs, remarked that "Our business differentiator is to offer clients a customized, responsive and proven approach to preclinical services. Xybion's Pristima solution fit right in with our strategy." Jeffrey Pallman, Associate Director of Toxicology, also noted: "We take pride in our track record in this industry. None of our programs have ever encountered problems at any regulatory agency because of program design, performance, or data collection. We selected Xybion as a partner after careful consideration of this legacy in the market."
After extensive research to improve its ability to bring near-real time data to our customerss, Calvert selected Xybion's Pristima solution to manage its general toxicology data as well as licensing Xybion's Standard Validation Package. Additionally, Calvert contracted Xybion to provide a full suite of professional services in order to achieve a tailored solution to match Calvert's needs.
About Calvert Labs: Calvert Laboratories provides contract services to pharmaceutical and biotechnology companies that will generate data and information necessary to file any regulatory submission with international government health service regulatory bodies. Calvert Labs services include acute, subchronic, chronic toxicology and carcinogenicity evaluations, safety pharmacology, discovery pharmacology, telemetry, pharmacokinetic studies, immunology and immunotoxicology. Calvert Labs (http://calvertlabs.com)
About Xybion Medical Systems: Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to Pristima, Xybion provides professional services, consulting, training and validation activities to clients throughout the world. Xybion Medical Systems (http://xybion.com)
###
Read the full story at http://www.prweb.com/releases/2009/10/prweb3128404.htm.
PRWeb.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
